Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Alexion Pharmaceuticals, Inc.

Understanding Best Care Practices for Hemorrhagic Stroke: A Focus on the Role of DOAC Reversals

Release Date: November 15, 2021
Expiration Date: November 15, 2022

Activity Overview

Increased risk of bleeding is a known complication of anticoagulation therapies, including direct oral anticoagulants (DOACs). Although DOACs demonstrated favorable safety and efficacy profiles in the absence of a specific reversal agent, situations such as overdose, serious bleeding, or the need for immediate surgery warranted a call to action to develop DOAC reversal agents. This call to action was answered, and there are now 2 FDA-approved DOAC reversal agents. Ongoing education about DOAC reversal is vital for clinicians involved in critical care. In this educational program, experts discuss the agents and best practices for the use of DOAC reversal in patients with intracranial hemorrhage.

This educational activity is an archive of the live virtual symposium held on October 27, 2021.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Alexion Pharmaceuticals, Inc.

Instructions for This Activity and Receiving Credit

Complete the activity (including pre- and post-activity assessments).
Answer the evaluation questions.
Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward neurointensivists, critical care clinicians, and neurologists. Cardiologists, nurse practitioners, physician assistant, nurses, primary care physicians, and other health care professionals involved in the treatment of patients experiencing bleeding episodes are invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Discuss intracerebral hemogghage (ICH) risk and assessment in patients on DOAC therapy
Evaluate the safety and efficacy of DOAC reversal agents
Review therapeutic management of ICH based on clinical indications and safety and efficacy data of DOAC reversal agents
Apply current practice guidelines on DOAC reversal therapies for optimal management of ICH and hemorrhagic stroke

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible companies.

Chair

Edward Manno, MD, MS
Vice Chair of Clinical Affairs
Department of Neurology
Northwestern University
Chicago, IL

Disclosures: Edward Manno, MD, MS, has no relevant financial relationships with commercial interests.

Faculty

Jennifer Frontera, MD
Professor, Department of Neurology
NYU Grossman School of Medicine
NYU Langone Health
New York, NY

Disclosures: Jennifer Frontera, MD, has no relevant financial relationships with commercial interests.

Jose Javier Provencio, MD
Louise Nerancy Professor in Neurology
Director, Nerancy Neuroscience Intensive Care Unit
University of Virginia
Charlottesville, VA

Disclosures: Jose Javier Provencio, MD, has no relevant financial relationships with commercial interests.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.